Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-κB activation

Plastic and Reconstructive Surgery

Volumn 120, Issue 7, 2007, Pages 1808-1818

  Park, Jong Woong ^b   Qi, Wen Ning ^a   Cai, Yongting ^b   Urbaniak, James R ^b   Chen, Long En ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; PHOSPHATE BUFFERED SALINE; PROTEASOME INHIBITOR; SYNAPTOTAGMIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; ATTENUATION; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CREMASTER MUSCLE; DOWN REGULATION; DRUG EFFECT; EDEMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUSCLE FLAP; MUSCLE ISCHEMIA; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REPERFUSION INJURY; SKELETAL MUSCLE; WESTERN BLOTTING;

ANIMALS; BLOOD VESSELS; BORONIC ACIDS; DRUG EVALUATION, PRECLINICAL; INTERCELLULAR ADHESION MOLECULE-1; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICROSCOPY, VIDEO; MUSCLE, SKELETAL; NF-KAPPA B P50 SUBUNIT; NITRIC OXIDE SYNTHASE TYPE II; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; PYRAZINES; RANDOM ALLOCATION; REPERFUSION INJURY; SURGICAL FLAPS; TYROSINE;

EID: 37349119748     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000287245.17319.57     Document Type: Article

References (53)

1. Ichikawa, H., Flores, S., Kvietys, P. R., et al. Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Circ. Res. 81: 922, 1997.
2. Yoshida, N., Granger, D. N., Anderson, D. C., et al. Anoxia/ reoxygenation-induced neutrophil adherence to cultured endothelial cells. Am. J. Physiol. 262: H1891, 1992.
3. Barker, J. E., Knight, K. R., Romeo, R., et al. Targeted disruption of the nitric oxide synthase 2 gene protects against ischaemia/reperfusion injury to skeletal muscle. J. Pathol. 194: 109, 2001.
4. Qi, W. N., Chen, L. E., Zhang, L., et al. Reperfusion injury in skeletal muscle is reduced in inducible nitric oxide synthase knockout mice. J. Appl. Physiol. 97: 1323, 2004.
5. Qi, W. N., Chaiyakit, P., Cai, Y., et al. NF-kappaB p65 involves in reperfusion injury and iNOS gene regulation in skeletal muscle. Microsurgery 24: 316, 2004.
6. Patel, P., Qi, W. N., Allen, D. M., et al. Inhibition of iNOS with 1400W improves contractile function and alters nos gene and protein expression in reperfused skeletal muscle. Microsurgery 24: 324, 2004.
7. Qi, W. N., Yan, Z. Q., Whang, P. G., et al. Gene and protein expressions of nitric oxide synthases in ischemia-reperfused peripheral nerve of the rat. Am. J. Physiol. 281: C849, 2001.
8. Zhang, L., Looney, C. G., Qi, W. N., et al. Reperfusion injury is reduced in skeletal muscle by inhibition of inducible nitric oxide synthase. J. Appl. Physiol. 94: 1473, 2003.
9. Gumina, R. J., Newman, P. J., Kenny, D., et al. The leukocyte cell adhesion cascade and its role in myocardial ischemiareperfusion injury. Basic Res. Cardiol. 92: 201, 1997.
10. Berti, R., Williams, A. J., Moffett, J. R., et al. Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury. J. Cereb. Blood Flow Metab. 22: 1068, 2002.
11. Jerome, S. N., Dore, M., Paulson, J. C., et al. P-selectin and ICAM-1-dependent adherence reactions: Role in the genesis of postischemic no-reflow. Am. J. Physiol. 266: H1316, 1994.
12. Campbell, B., Adams, J., Shin, Y. K., et al. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J. Mol. Cell. Cardiol. 31: 467, 1999.
13. Clemens, J. A. Cerebral ischemia: Gene activation, neuronal injury, and the protective role of antioxidants. Free Radic. Biol. Med. 28: 1526, 2000.
14. Donnahoo, K. K., Meldrum, D. R., Shenkar, R., et al. Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney. J. Urol. 163: 1328, 2000.
15. Zou, L., Attuwaybi, B., and Kone, B. C. Effects of NF-kappa B inhibition on mesenteric ischemia-reperfusion injury. Am. J. Physiol. 284: G713, 2003.
16. Williams, A. J., Hale, S. L., Moffett, J. R., et al. Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J. Cereb. Blood Flow Metab. 23: 75, 2003.
17. Lille, S. T., Lefler, S. R., Mowlavi, A., et al. Inhibition of the initial wave of NF-kappaB activity in rat muscle reduces ischemia/ reperfusion injury. Muscle Nerve 24: 534, 2001.
18. Li, C., Browder, W., and Kao, R. L. Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart. Am. J. Physiol. 276: H543, 1999.
19. Chandrasekar, B., Smith, J. B., and Freeman, G. L. Ischemiareperfusion of rat myocardium activates nuclear factor-kappaB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation 103: 2296, 2001.
20. Fan, H., Sun, B., Gu, Q., et al. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am. J. Physiol. 282: H1778, 2002.
21. Meldrum, K. K., Hile, K., Meldrum, D. R., et al. Simulated ischemia induces renal tubular cell apoptosis through a nuclear factor-kappaB dependent mechanism. J. Urol. 168: 248, 2002.
22. Serracino-Inglott, F., Habib, N. A., and Mathie, R. T. Hepatic ischemia-reperfusion injury. Am. J. Surg. 181: 160, 2001.
23. Stephenson, D., Yin, T., Smalstig, E. B., et al. Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 20: 592, 2000.
24. Kis, A., Yellon, D. M., and Baxter, G. F. Role of nuclear factor-kappaB activation in acute ischaemia-reperfusion injury in myocardium. Br. J. Pharmacol. 138: 894, 2003.
25. Zingarelli, B., Hake, P. W., Yang, Z., et al. Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappaB and AP-1 activation and enhances myocardial damage. F.A.S.E.B. J. 16: 327, 2002.
26. Adams, J. The proteasome: Structure, function, and role in the cell. Cancer Treat. Rev. 29 (Suppl. 1): 3, 2003.
27. Pye, J., Ardeshirpour, F., McCain, A., et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am. J. Physiol. 284: H919, 2003.
28. Bao, J., Sato, K., Li, M., et al. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am. J. Physiol. 281: H2612, 2001.
29. Russell, J., Epstein, C. J., Grisham, M. B., et al. Regulation of E-selectin expression in postischemic intestinal microvasculature. Am. J. Physiol. 278: G878, 2000.
30. Chen, L. E., Seaber, A. V., and Urbaniak, J. R. Vasodilator action of prostaglandin E1 on microcirculation of rat cremaster muscle. Microsurgery 11: 204, 1990.
31. Park, J. W., Qi, W. N., Cai, Y., et al. Skeletal muscle reperfusion injury is enhanced in extracellular superoxide dismutase knockout mouse. Am. J. Physiol. 289: H181, 2005.
32. Phillips, J. B., Williams, A. J., Adams, J., et al. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 31: 1686, 2000.
33. Carroll, J. E., Hess, D. C., Howard, E. F., et al. Is nuclear factor-kappaB a good treatment target in brain ischemia/ reperfusion injury? Neuroreport 11: R1, 2000.
34. Gilmore, T. D. The Rel/NF-kappaB signal transduction pathway: Introduction. Oncogene 18: 6842, 1999.
35. Xie, Q. W., Kashiwabara, Y., and Nathan, C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269: 4705, 1994.
36. Elliott, P. J., Zollner, T. M., and Boehncke, W. H. Proteosome inhibition: A new anti-inflammatory strategy. J. Mol. Med. 81: 235, 2003.
37. Katsuyama, K., Shichiri, M., Marumo, F., et al. NO inhibits cytokine-induced iNOS expression and NF-kappaB activation by interfering with phosphorylation and degradation of IkappaB-alpha. Arterioscler. Thromb. Vasc. Biol. 18: 1796, 1998.
38. de Vera, M. E., Shapiro, R. A., Nussler, A. K., et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: Initial analysis of the human NOS2 promoter. Proc. Natl. Acad. Sci. U.S.A. 93: 1054, 1996.
39. Nathan, C. Inducible nitric oxide synthase: Regulation subserves function. Curr. Top. Microbiol. Immunol. 196: 1, 1995.
40. Goldring, C. E., Narayanan, R., Lagadec, P., et al. Transcriptional inhibition of the inducible nitric oxide synthase gene by competitive binding of NF-kappa B/Rel proteins. Biochem. Biophys. Res. Commun. 209: 73, 1995.
41. Naidu, B. V., Fraga, C., Salzman, A. L., et al. Critical role of reactive nitrogen species in lung ischemia-reperfusion injury. J. Heart Lung Transplant. 22: 784, 2003.
42. Wolin, M. S. Interactions of oxidants with vascular signaling systems. Arterioscler. Thromb. Vasc. Biol. 20: 1430, 2000.
43. Sun, B., Fan, H., and Honda, T. Activation of NF kappa B and expression of ICAM-1 in ischemic-reperfused canine myocardium. J. Mol. Cell. Cardiol. 33: 109, 2001.
44. Cuzzocrea, S., Chatterjee, P. K., and Mazzon, E. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br. J. Pharmacol. 135: 496, 2002.
45. Ohta, K., Nakayama, K., and Kurokawa, T. Inhibitory effects of pyrrolidine dithiocarbamate on endotoxin-induced uveitis in Lewis rats. Invest. Ophthalmol. Vis. Sci. 43: 744, 2002.
46. Liu, S. F., Ye, X., and Malik, A. B. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 100: 1330, 1999.
47. Howard, E. F., Chen, Q., and Cheng, C. NF-kappa B is activated and ICAM-1 gene expression is upregulated during reoxygenation of human brain endothelial cells. Neurosci. Lett. 248: 199, 1998.
48. Squadrito, F., Altavilla, D., and Squadrito, G. Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia-reperfusion injury. J. Mol. Cell. Cardiol. 32: 429, 2000.
49. Kupatt, C., Habazettl, H., and Goedecke, A. Tumor necrosis factor-alpha contributes to ischemia- and reperfusion-induced endothelial activation in isolated hearts. Circ. Res. 84: 392, 1999.
50. Gao, Y., Lecker, S., and Post, M. J. Inhibition of ubiquitinproteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J. Clin. Invest. 106: 439, 2000.
51. Sunwoo, J. B., Chen, Z., and Dong, G. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7: 1419, 2001.
52. Orlowski, R. Z., Stinchcombe, T. E., and Mitchell, B. S. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20: 4420, 2002.
53. Hideshima, T., Chauhan, D., and Richardson, P. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 277: 16639, 2002.